Cadrenal Therapeutics Reports Mixed Phase 2 Results for CAD-1005 in HIT; Advances to FDA End-of-Phase 2 Meeting

summarizeResumen

Cadrenal Therapeutics' Phase 2 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT) presented mixed results. While the primary endpoint of platelet count recovery rate was not met, the drug demonstrated an encouraging reduction in thrombotic events in the secondary endpoint analysis. This suggests a potential clinical benefit despite the primary endpoint miss. The company's decision to proceed with an End-of-Phase 2 meeting with the FDA in March 2026 is a critical next step, indicating a potential path forward for Phase 3 development. Investors should monitor the outcome of this FDA meeting for clarity on the drug's regulatory future and the company's strategy for this first-in-class 12-LOX inhibitor.

check_boxEventos clave

• Phase 2 Trial Results Announced

  The company reported results from its Phase 2 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT).

• Primary Endpoint Missed

  The trial did not meet its primary endpoint of platelet count recovery rate.

• Encouraging Secondary Endpoint Data

  CAD-1005 showed a greater than 25% absolute reduction in thrombotic events compared to placebo, though the study was not powered for statistical significance on this secondary endpoint.

• FDA End-of-Phase 2 Meeting Scheduled

  An End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) is scheduled for March 2026 to discuss a Phase 3 registration path for CAD-1005.

auto_awesomeAnalisis

Cadrenal Therapeutics' Phase 2 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT) presented mixed results. While the primary endpoint of platelet count recovery rate was not met, the drug demonstrated an encouraging reduction in thrombotic events in the secondary endpoint analysis. This suggests a potential clinical benefit despite the primary endpoint miss. The company's decision to proceed with an End-of-Phase 2 meeting with the FDA in March 2026 is a critical next step, indicating a potential path forward for Phase 3 development. Investors should monitor the outcome of this FDA meeting for clarity on the drug's regulatory future and the company's strategy for this first-in-class 12-LOX inhibitor.